Kalaris Therapeutics (KLRS) News
NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.28-0.07 (-5.19%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KLRS news summary
We found 2 recent headlines mentioning Kalaris Therapeutics (KLRS): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. KLRS is making an outsized move today, down 5.19% at $1.28, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Kalaris Therapeutics Reports Q3 Net Loss", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kalaris Therapeutics headlines
- Kalaris Therapeutics Reports Q3 Net Loss(RTTNews) - Kalaris Therapeutics, Inc. (KLRS) on Tuesday, reported a lower net loss for the third quarter of 2026 compared with the same period in 2025, as operating expenses declined and other…Nasdaq
- Kalaris Reports Third Quarter 2026 Financial Results and Provides Business UpdatePreliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027GlobeNewswire